{"id":"NCT02686658","sponsor":"IVERIC bio, Inc.","briefTitle":"Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","officialTitle":"A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimuraâ„¢ (Anti-C5 Aptamer) in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-12-15","primaryCompletion":"2019-09-26","completion":"2020-04-23","firstPosted":"2016-02-19","resultsPosted":"2023-05-11","lastUpdate":"2025-06-10"},"enrollment":286,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Geographic Atrophy","Dry Age-Related Macular Degeneration"],"interventions":[{"type":"DRUG","name":"Avacincaptad Pegol","otherNames":["Zimura (previous name)","IZERVAY","ARC1905"]},{"type":"OTHER","name":"Sham","otherNames":[]}],"arms":[{"label":"Avacincaptad Pegol 1 mg [Part 1]","type":"EXPERIMENTAL"},{"label":"Avacincaptad Pegol 2 mg [Part 1]","type":"EXPERIMENTAL"},{"label":"Sham [Part 1]","type":"SHAM_COMPARATOR"},{"label":"Avacincaptad Pegol 2 mg (Avacincaptad Pegol 2mg+Sham) [Part 2]","type":"EXPERIMENTAL"},{"label":"Avacincaptad Pegol 4 mg (Avacincaptad Pegol 2mg+Avacincaptad Pegol 2mg) [Part 2]","type":"EXPERIMENTAL"},{"label":"Sham (Sham+Sham) [Part 2]","type":"SHAM_COMPARATOR"}],"summary":"The objectives of this study were to evaluate the safety and efficacy of Zimura intravitreal (IVT) administration when administered in participants with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).","primaryOutcome":{"measure":"Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence","timeFrame":"Baseline and 12 months","effectByArm":[{"arm":"Zimura 2 mg [Part 1 & Part 2 Combined]","deltaMin":0.292,"sd":0.077},{"arm":"Sham [Part 1 & Part 2 Combined]","deltaMin":0.402,"sd":0.075},{"arm":"Zimura 4 mg [Part 2]","deltaMin":0.321,"sd":0.074},{"arm":"Sham [Part 2]","deltaMin":0.444,"sd":0.072}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0072"},{"comp":"OG002 vs OG003","p":"0.0051"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":78,"countries":["United States","Croatia","Czechia","Estonia","Hungary","Israel","Latvia"]},"refs":{"pmids":["32882310","39538001","37314061"],"seeAlso":["https://www.trialsummaries.com/Study/StudyDetails?id=26398&tenant=MT_AST_9011"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":26},"commonTop":["Conjunctival haemorrhage *","Urinary tract infection","Neovascular age-related macular degeneration*","Intraocular pressure increased","Fall"]}}